CMS certification 393303
Children's Hospital of Philadelphia
3401 Civic Center Blvd, Philadelphia, PA 19104
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.
Not reported for this hospital
CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.
Clinicians registered at this address
2,461 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 45 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Pediatrics | 860 |
| Pediatric Hematology-Oncology | 116 |
| Pediatric Critical Care Medicine | 90 |
| Pediatric Gastroenterology | 89 |
| Pediatric Emergency Medicine | 87 |
| Pediatric Anesthesiology | 84 |
| Pediatric Cardiology | 84 |
| Neonatal-Perinatal Medicine | 77 |
| Physician Assistant | 65 |
| Neurology with Special Qualifications in Child Neurology | 62 |
| Pediatrics, Critical Care | 51 |
| Pediatric Endocrinology | 45 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $21.1M
- 2020 $20.4M
- 2021 $29.4M
- 2022 $0
- 2023 $0
- 2024 $28.6M
- 2025 $34.2M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Royalties and licensing fees | $974,794 | 29 |
| Grants | $581,781 | 16 |
| Speaking, teaching and other services | $200,050 | 82 |
| Medical devices and supplies on long-term loan | $60,578 | 10 |
| Space rental and facility fees | $23,250 | 17 |
| Consulting fees | $6,480 | 1 |
| Debt forgiveness | $3,771 | 5 |
| Education | $3,500 | 2 |
| Charitable contributions | $3,430 | 34 |
| Honoraria | $190 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Pfizer INC. | $10.1M | 48 |
| Kite Pharma, Inc. | $1.9M | 34 |
| Novartis Pharmaceuticals Corporation | $1.8M | 18 |
| Ionis Pharmaceuticals, Inc. | $1.5M | 92 |
| Spark Therapeutics, Inc. | $1.5M | 51 |
| ModernaTX, Inc. | $1.4M | 101 |
| Sarepta Therapeutics, Inc. | $1.4M | 176 |
| Ultragenyx Pharmaceutical Inc. | $1.1M | 87 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A PHASE 3 RANDOMIZED TRIAL OF INOTUZUMAB OZOGAMICIN FOR NEWLY DIAGNOSED HIGHRISK BALL RISK ADAPTED POSTINDUCTION THERAPY FOR HIGHRISK BALL MIXED PHEN… PFIZER INC. | $7.2M |
| A PHASE 2 STUDY OF INOTUZUMAB OZOGAMICIN IN CHILDREN AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY CD22 BACUTE LYMPHOBLASTIC LEUKEMIA BALL PFIZER INC. | $2.7M |
| Phase 1 Trial of GPC2-Directed Chimeric Antigen Receptor Autologous T cell (GPC2 CAR T)for Relapsed or Refractory Neuroblastoma and Metastatic Retino… Kite Pharma, Inc. | $1.4M |
| Long Term Follow Up of Patients Exposed to Lentiviral Based CD19 Directed CAR T Cell Therapy Novartis Pharmaceuticals Corporation | $1.2M |
| SRP-9001-303 Sarepta Therapeutics, Inc. · NCT05881408 | $1.1M |
| A STUDY OF INTRATHECAL SHP611 IN PARTICIPANTS WITH LATE INFANTILE METACHROMATIC LEUKODYSTROPHY Takeda Pharmaceuticals U.S.A., Inc. · NCT03771898 | $1M |
| The LiFFT Study (Lurbinectedin in FET-Fusion Tumors) JAZZ PHARMACEUTICALS INC. | $900,000 |
| A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study ModernaTX, Inc. · NCT05130437 | $702,841 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Children's Hospital of Philadelphia
Does Children's Hospital of Philadelphia have an emergency room?
Yes. CMS lists emergency services at Children's Hospital of Philadelphia.
Does Children's Hospital of Philadelphia receive money from drug and device companies?
Drug and device makers reported $34.2M in payments to Children's Hospital of Philadelphia for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.